logo-loader

Silence Therapeutics 'honour-bound' to attack and defend their patents - CEO Ali Mortazavi

Published: 19:20 16 May 2017 AEST

Ali Mortazavi, chief executive of Silence Therapeutics PLC (LON:SLN) breaks down the detail to Proactive's Andrew Scott on why they're seeking payments from a number of developers for drugs already in late-stage development.

Mortazavi adds that they've also filed for more patent protection for their RNA therapeutics/gene silencing technology.

OzAurum to start drilling at Boca Rica Lithium Project

OzAurum Resources Ltd (ASX:OZM) CEO and managing director Andrew Pumphrey sits down with Proactive’s Jonathan Jackson to discuss an upcoming drilling program at Boca Rica Lithium Project in Brazil, following the identification of a spodumene zone. The company plans to start drilling in the next...

4 hours, 22 minutes ago